The CoreValve™/Evolut™ platform provides reproducible results from clinical trial to the real world.
Explore our STS/ACC TVT Registry™* data that support the excellent clinical performance seen in our trials.
Published data with the TVT Registry™* highlighted the continued downward trend of permanent pacemakers (PPI) with the Evolut™ platform.
The data suggest the adoption of procedural techniques, such as cusp overlap, coupled with advancements in valve design, contribute to declining PPI rates (14.7% in 2018 Q3 to 8.8% in 2021 Q2 for in-hospital PPI rate).
N = 54,014
Evolut™ R/Evolut™ PRO/Evolut™ PRO+
In-hospital pacemaker rates by quarter
These rates exclude baseline PPI/ICD and include TAV-in-SAV and TAV-in-TAV treated patients.
TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
At EuroPCR 2021, Dr. Bajwa presented the first large report of the Evolut™ PRO+ system, including comparisons between the Evolut™ R and Evolut™ PRO+ 34 mm valve size.
Evolut™ PRO+ valves, with a pericardial wrap on all valve sizes, demonstrated lower total aortic regurgitation (AR) compared to Evolut™ R valves with low rates of moderate AR (1.9% versus 2.0%) and mild AR (27.8% versus 34.8%) at one month.
Among 34 mm valves, ≥ mild AR was numerically lower at one month in patients treated with the Evolut™ PRO+ system compared to those treated with Evolut™ R valves (p = 0.071).
N = 525 Evolut™ R; N = 3,963 Evolut™ PRO+
Evolut™ R 11.7%/Evolut™ PRO+ 88.3%
Total AR at 30 days
† P-value is comparing milder or greater total aortic regurgitation between groups.
TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
Review the latest data supporting the Evolut™ platform.
Discover our procedural guidance and outcomes you can expect from the Evolut™ platform.
Medtronic Academy offers a wide range of resources for the Evolut™ TAVR platform.
The Confida™ Brecker guidewire is specifically designed for transcatheter aortic valve replacement (TAVR) procedures.
The Evolut™ FX transcatheter aortic valve replacement (TAVR) system sets new expectations for precision, control, and predictability in TAVR procedures.
The Evolut™ FX+ transcatheter aortic valve system is designed with specific features intended to enable lifetime management solutions such as coronary access.
The Evolut™ PRO+ TAVR system features the lowest delivery profile for 23–29 mm valves and advanced sealing with an external tissue wrap on all valve sizes.
™* Third-party brands are trademarks of their respective owners.